New personalized vaccine takes on tough cancers
NCT ID NCT07587827
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a personalized cancer vaccine called ODI-2001 in 77 people with advanced colon or pancreatic cancer that has spread or cannot be removed. The vaccine is custom-made for each patient's tumor and is given along with a drug that boosts the immune system. The main goals are to find a safe dose and see if the vaccine can help slow the cancer's growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- personalized cancer vaccine (DNA neoantigen vaccine + MVA viral vector + ipilimumab)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced colon and pancreatic cancers that are hard to treat.
- What could go wrong
- This is a very early Phase 1 trial with only 77 people. It is designed mainly to check safety and find the right dose, not to prove it works. The vaccine is personalized, so it may not work for everyone, and side effects from the immune-boosting drugs could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU Jean Minjoz
Besançon, 25000, France
-
Centre Georges-François Leclerc
Dijon, 21000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Can mindfulness together ease the burden of advanced cancer?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can three common drugs boost chemotherapy against pancreatic cancer?